Comparison 2. Ivermectin compared to placebo or standard of care for people with mild COVID‐19 treated in the outpatient setting.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
2.1 All‐cause mortality up to 28 days (primary analysis)	2	422	Risk Ratio (M‐H, Random, 95% CI)	0.33 [0.01, 8.05]
2.2 Worsening of clinical status – need for invasive mechanical ventilation up to 14 days (primary analysis)	1	398	Risk Ratio (M‐H, Random, 95% CI)	2.97 [0.12, 72.47]
2.3 Worsening of clinical status – need for non‐invasive mechanical ventilation or high flow up to 14 days (primary analysis)	1	398	Risk Ratio (M‐H, Random, 95% CI)	Not estimable
2.4 Symptom resolution – number of participants with symptoms resolved up to 14 days (primary analysis)	1	398	Risk Ratio (M‐H, Random, 95% CI)	1.04 [0.89, 1.21]
2.5 Duration to symptom resolution (secondary analysis)	1	62	Mean Difference (IV, Random, 95% CI)	‐1.02 [‐2.76, 0.72]
2.6 Any adverse events within 28 days (primary analysis)	2	422	Risk Ratio (M‐H, Random, 95% CI)	0.95 [0.86, 1.05]
2.7 Serious adverse events within 28 days (primary analysis)	2	422	Risk Ratio (M‐H, Random, 95% CI)	0.99 [0.14, 6.96]
2.8 Viral clearance at 7 days (primary analysis)	1	24	Risk Ratio (M‐H, Random, 95% CI)	3.00 [0.13, 67.06]
2.9 Viral clearance at 14 days (secondary analysis)	1	40	Risk Ratio (M‐H, Random, 95% CI)	0.95 [0.79, 1.13]